About US
Contact us
-
Johnson & Johnson completes acquisition of Alios BioPharma for $1.75bnUS-based Johnson & Johnson (J&J) has completed the acquisition of a privately held clinical stage biopharmaceutical company, Alios BioPharma, for $1.75bn in cash. Based in California, US, Ali2014/11/11
-
Aegerion to acquire AstraZeneca’s lipodystrophy treatment Myalept for $325mAegerion Pharmaceuticals has signed an agreement to acquire an orphan product Myalept (metreleptin for injection) from AstraZeneca. AstraZeneca will receive $325m upfront payment to divest the rights2014/11/11
-
The International Clinical Trials Registry Platform – perils, pitfalls and possibilitiesAn intriguing study, published in the August edition of the journal PAIN, has shed new light on the issue of publication bias. Investigators using the World Health Organization’s International Clini2014/11/10
-
The amendment, including two bedaquiline-containing treatment arms, will be known as Stream 2. It is part of the post-approval requirements for bedaquiline from both US Food and Drug Administration (FDA) and European Medicines Agency (EMA), and is accepted as an alternative to the initially planned Phase III trial of Sirturo.As clinical trials continue to grow in size and complexity, more and more companies are adopting software-as-a-service applications as an effective means of data management, without the hassle of bu2014/11/10
-
Janssen and The Union collaborate to evaluate bedaquiline in MDR-TBJanssen Research & Development has partnered with the International Union Against Tuberculosis and Lung Disease (The Union) to include Sirturo (bedaquiline) in the Stream study. The Stream study2014/11/10
-
GSK seeks regulatory approvals for eosinophilic asthma drug in US and EuropeBritish drug-maker GlaxoSmithKline (GSK) has submitted regulatory applications in the US and Europe for approval of its to treat patients with severe eosinophilic asthma. Mepolizumab is an investigat2014/11/7
-
Abide Therapeutics and University of Oxford to explore new drug targetsAbide Therapeutics has partnered with the University of Oxford and the Oxford University Hospitals NHS Trust to examine the therapeutic potential of serine hydrolases, the enzyme classes with validate2014/11/7
-
A New Formulation Line for Insulin VialsThe Danish pharmaceutical group Novo Nordisk has chosen Bürkert, the fluid control specialists, to equip its latest production line for the formulation of insulin vials at its site in Chartres, France2014/11/7
-
Roche’s Basel Site Expansion, Basel, SwitzerlandRoche, the world's fourthbiggest pharmaceutical companyof 2014, announced its investment plans on a major infrastructure development project at its Basel site in Switzerland in October 2014. The deve2014/11/6
-
BMS signs exclusive option deal to buy Danish Galecto BiotechBristol-Myers Squibb (BMS) has entered into an exclusive option agreement to acquire Denmark-based Galecto Biotech and receive worldwide rights to its inhaled inhibitor of galectin-3, TD139. Galectin2014/11/6